Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
Novartis has maintained a consistent approach to its capital
allocation priorities; initiating up-to USD 15bn share buyback
STRATEGY
Investing in the business
Investments in organic business¹
USD 43bn of R&D 2018-2022
USD 6bn of CAPEX 2018-2022
Returning to shareholders
USD 59bn distributed² 2018-2022
Growing annual dividend in CHF
USD 35bn of dividends 2018-2022
USD 7.3bn paid out in Q1-2023
Value-creating bolt-ons
USD 30bn (approx.) 2018-2022
Substantial
cash
generation
No rebasing post planned Sandoz spin-off
Chinook³, Avrobio4, DTX Pharma acquisition
'
Share buybacks (SBB)
USD 24bn of buybacks 2018-2022
USD 15bn SBB (announced Dec 2021)
completed in June 2023
SBB of up to USD 15bn planned to be
completed by end 2025
1. Core R&D and CAPEX actuals 2018-2022. 2. Through dividends and share buybacks. 3. Subject to customary closing conditions; closing expected H2 2023.
4. Acquisition of Avrobio cystinosis program.
21 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation